
Soviet Spacecraft Cosmos 482 Location After Reentry Baffling Watchers
The likely fate of Cosmos 482.
The super-tough Soviet space probe that left Earth 53 years ago on a mission for Venus it never came close to completing has finally come home, ending a very long detour in orbit. While everyone agrees that Cosmos 482 (also sometimes Kosmos 482) has stopped flying, there's little agreement on where it crash or splash landed.
The Venera initiative lander launched in 1972 but a malfunction soon left it trapped around Earth. It was a subject of fascination in recent weeks after it became clear its orbit was decaying to an eventual impact. The rugged titanium spacecraft was built to withstand conditions on Venus, meaning it had a very good chance of surviving a trip through Earth's atmosphere to crash land somewhere on our surface.
Space agencies and other trackers use different models to estimate where and when Cosmos 482 might have re-entered the atmosphere, and without any direct observations or much other data, these 'best guesses' are about all we have to go on about its final resting place. And these estimates place that spot either in the South Pacific, somewhere in western Europe, the Indian Ocean or in or offshore of western Australia.
It's quite a range. The lack of any fireball sightings or other credible observations suggests a remote, watery resting place, which was always the most likely outcome. But the reality is we simply don't know.
Cosmos 482 was set to make four passes over Germany during the reentry window. It was seen by European Space Agency radar systems during the first two of these passes, at approximately 04:30 UTC and 06:04 UTC, but never again.
The expected ground track during the reentry window of Cosmos 482.
"As the descent craft was not spotted by radar over Germany at the expected 07:32 UTC / 09:32 CEST pass, it is most likely that the reentry has already occurred," the ESA reported
The European Union Space Surveillance and Tracking Operations Center reportedber Saturday morning that it had narrowed the re-entry window for Cosmos 482 to a total period of just 20 minutes, centered on the part of the spacecraft's journey when it would have been flying over central Europe, including the UK, Germany and Poland. However, the EUSST cautions that the entirety of the 40 minute window also encompasses a long arc stretching from northernmost South America to the Bay of Bengal.
The EU ground track map for Cosmos 482.
After staying quiet on the impending fate of Cosmos 482 all through the build up to its reentry, Russian leadership finally made a statement on its belief about the final resting place of the probe.
Roscosmos, the Russian Space Agency reports that 'the spacecraft entered the dense layers of the atmosphere at 9:24 Moscow time, 560 km west of Middle Andaman Island, and fell into the Indian Ocean west of Jakarta.'
Meanwhile, experienced orbit watcher Marco Langbroek places re-entry off the coast of Australia and US Space Force data puts it in the South Pacific.
This disagreement may not be as significant as it seems. All the predictions are essentially looking at the same orbital track of Cosmos 482 and then running different models that try to account for a number of variables like space weather, atmospheric conditions, the composition of the spacecraft and other factors. Because reentering objects travel at such high speeds, small disagreements in these models lead to different results separated by thousands of miles.
The reality is simply that we don't have enough data. In the past, government data from a sensor network used to detect nuclear detonations has been used to help pinpoint the impact point of space junk or meteoroids. It's still possible we might see that sort of data, helpful information from weather satellites, lightning mappers and visual sightings slowly roll in to better establish the last resting place of a venerable, if wayward, spacecraft.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Trail cam solves mystery after gruesome find next to Aussie dam: 'Very precise'
A trail camera in a rural Queensland town has captured an incredible act of evolution by an Australian animal. On the edge of a dam, the camera filmed the moment a rakali, a native water rat, takes down its prey – a poisonous cane toad that the rodent has adapted to eat, leaving behind nothing but the skin, bones and toxic glands. Cane toads are the result of one of Australia's worst environment blunders, originally introduced in Queensland in 1935 to help control pest beetles in Queensland. The invasive frogs are now spreading across the north of the country, and towards the southwest, at a rate of up to 50km per year, with experts struggling to stop the march of the toad. While the toads do have predators, there are not many who are able to eat one and live to tell the tale. The poisonous skin glands in its shoulders kill goannas, quolls, snakes and even crocodiles. One native animal who has learned to fight back against the destructive species is the rakali, a large aquatic rat found in all states and territories. The highly intelligent rodents learned to hunt and kill cane toads in less than two years after the toads moved into their habitat, a study from the University of Melbourne found. When Hayley Troupe found a dead cane toad by her dam in Blackbutt, in southeast Queensland, she had an inkling there could be a rakali behind it. 'There was a lot of precision because all of the skin was there, the poisonous glands on the back were still there, and there was bits of bone around,' she told Yahoo News. 'It was obviously something that's been very precise in its eating and obviously skilled at eating it without eating the poisonous bits.' While she'd never seen a rakali on her land before, she had a trail cam that she regularly set up around her five-acre property and decided to move it close to the water's edge to catch the elusive animal in action. Two days later, her camera recorded the moment a rakali attacked a cane toad, showing how it flips the toad on to its back to avoid the poison glands. Rakali commonly target larger toads and will eat their heart and liver. They've been known to move the gall bladder — which contains toxic bile salts — out of the way and also remove the skin off the toad's legs before consuming the muscle. Hayley, 35, said the rat must've had a 'feast' as she'd found about 10 other toad carcasses in the days that followed. 'It's great that they've learned that, but it's a shame that a lot of the other native species haven't yet. There's a lot of species that are suffering because of cane toads, like quolls, for example. They haven't worked out how to eat them safely,' she said. Hayley, who works for Queensland Conservation Council as their Nature Organiser, shared the video on the QCC Facebook page where it quickly garnered more than 1.3 million views. 'It shows you that people love nature and they like learning about it. But I guess it would be nice if we could get that sort of enthusiasm in protecting nature as well, and pushing our governments to protect habitat," she said. Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
Yahoo
an hour ago
- Yahoo
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million from existing specialist investors, including The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Paris, France – June 12, 2025Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial. New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in the round, of which $5 million will be allocated to Enterome upon closing and an additional $4 million in conditional tranched funding. Existing shareholders invested an additional $10 million including: SymBiosis, a U.S. venture capital firm; Seventure Partners, based in France; Lundbeckfonden BioCapital from Denmark; Primo Capital, an Italian venture capital and private equity firm; and The U.S. Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP). 'Attracting highly specialized blood cancer investor IFLI to this financing demonstrates the conviction of our new and existing investors in the potential of OncoMimics™ for blood and solid tumor cancers,' said Pierre Bélichard, Enterome's Chief Executive Officer. 'We currently are generating exciting clinical proof of concept data for EO2463 monotherapy in several iNHL patient populations included in the Phase 1/2 SIDNEY clinical trial. Most importantly, EO2463 has shown robust clinical efficacy and exceptional safety and tolerability – which is especially impressive for such a potent immunotherapy. This offers a new hope for these patients and a rare opportunity to create an entirely new market segment for an impactful therapeutic. This financing will enable us to continue the SIDNEY trial of EO2463 and prepare to launch a first pivotal Phase 3 trial of this candidate for the 'watch-and-wait' iNHL population.' The company presented interim SIDNEY dataat the American Society of Hematology (ASH) conference in December 2024, showing highly encouraging responses in the Cohort 2 of 'watch and wait' iNHL patients in the ongoing SIDNEY study. This population, as the name suggests, is generally not eligible to receive other treatments due to the unacceptable risk-benefit ratio (in this iNHL sub-population) of the most commonly used blood cancer therapies. The company also recently disclosed having held positive meetings with both FDA (Type C meeting) and EMA (Scientific Advice), outlining a clear regulatory path registration for marketing authorizations in 'watch-and-wait' iNHL. 'This investment aligns with IFLI's mission to accelerate the development of innovative therapies and precision biomarkers for follicular lymphoma,' said Michel Azoulay, MD, Chief Medical Officer at IFLI. 'EO2463 represents a novel class of synthetic, off-the-shelf Immunotherapeutics with a unique mechanism of action that selectively targets malignant B cells. We are particularly interested in supporting Enterome's efforts to demonstrate EO2463's clinical efficacy across multiple lines of therapy, including in relapsed and refractory settings.' Enterome recently announced that it will present new data showing EO2463 also has a meaningful impact when tested in combination with standard of care in relapsed and refractory iNHL patients at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21. Previous findings presented at ASCO in 2024 in the relapsed and refractory patient population further suggested the potential to identify individuals most likely to benefit from EO2463 treatment, supported by biomarker analyses. Lore Gruenbaum, Chief Scientific Officer at LLS, said, 'It is important for us to continue to support Enterome, a company working to develop novel therapeutics based on our shared commitment to create better therapies for blood cancers. LLS has invested over $1.8 billion in groundbreaking research since our inception in 1949. Our active partnership with Enterome, through our Therapy Acceleration Program, will continue to advance the clinical development of the OncoMimics™ family of novel immunotherapeutics for the benefit of blood cancer patients. We are particularly excited to help advance EO2463 which has shown promising signs of efficacy as monotherapy with excellent safety and tolerability in 'watch-and-wait' iNHL patients, who currently have no approved treatment options.' EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimics™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that mimic the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells' capacity to develop immune-resistance mechanisms such as antigen escape. SIDNEY is an ongoing 12-month open label Phase 1/2 study that aims to assess safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in up to about 55 patients with follicular lymphoma and marginal zone lymphoma including divided into three cohorts: newly diagnosed patients eligible to watch-and-wait (monotherapy); newly diagnosed patients in need of therapy / first line (combo with rituximab); patients with relapsed/refractory disease (combo with R2). In addition to safety, survival, response rates and other measures of efficacy are being collected. OncoMimics™ were inspired by the microbial origin of certain autoimmune diseases. The Company uses AI and machine learning to identify microbial proteins that closely mimic the structure, effect or actions of specific cancer antigens (as well as hormones or cytokines). Memory T cells against microbial antigen are created during early development, sometimes leading to autoimmune disorders. In the case of OncoMimics™, however, this means that the immune system can mount a rapid, robust and durable immune response that is highly targeted and specific for the OncoMimics™ and the cancer antigens they closely resemble. This is possible because, unlike cancer antigens, OncoMimics™ bypass the biological process, known as thymic deletion, that prevents the immune system from mounting an attack against the 'self' proteins (e.g. antigen) on tumor and blood cancer cells. Once activated, the immune system attacks with high specificity and potency the cancer antigens targeted by the OncoMimics™, killing the cancer cells that carry them. OncoMimics™ are synthetic peptides that are easy to manufacture, store, distribute and administer as an off-the-shelf subcutaneous injection. In clinical testing to date they have been shown to be extremely well tolerated, especially compared to other potent immunotherapies. Enterome SA ( is a privately held clinical-stage biopharmaceutical company developing OncoMimics™, a new proprietary immunotherapeutic modality inspired by the microbial origin of certain autoimmune diseases, to treat cancer. The Company's wholly-owned OncoMimics™ pipeline includes three distinct clinical-stage drug candidates: EO2463 to treat indolent non-Hodgkin lymphomas; EO4010 to treat third-line colorectal cancer; and EO2401 to treat glioblastoma and adrenal tumors. Each of these candidates has shown positive early clinical efficacy and exceptional safety and tolerability. For more information, please contact: ENTEROME INVESTOR & MEDIA RELATIONS Pierre BélichardChief Executive Officer +33 (0)1 75 77 27 85 Cohesion BureauChris Maggos / Giovanni Ca' Zorzi +41 (0)79 367 6254 / +33 (0)7 84 67 07 27enterome@ Attachment 20250612_Enterome _PR_Funding_Round_finalError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
We can cure baldness, claim scientists
Anxiously checking in the mirror for signs of male pattern baldness may be a thing of the past, as scientists in Madrid believe they have found a way to reverse hair loss. Researchers at the San Carlos clinic in the Spanish capital claim they were able to regrow hair on mice in almost all cases during an experimental stem cell treatment study. The project involved giving male and female mice dihydrotestosterone, a by-product of testosterone that causes receding hair lines in men and thinning hair in women. Once the rodents had lost all their fur, half of them were injected with stem cells taken from body fat as well as a chemical called adenosine triphosphate, which stimulates cellular growth. The other half were given a placebo. All the male mice given the stem cell-chemical cocktail experienced hair regrowth, with around half getting back all their fur. The majority of the female mice also regrew their coats. 'Hair grew back in all of the treated male mice. In the case of the females, a lower dose was used, and the results were also somewhat worse, although still good, because 90 per cent managed to repopulate their hair,' Dr Eduardo López Bran, head of dermatology at the San Carlos, explained. The scientists, whose work was published in Stem Cell Research & Therapy, say that it will still be four or five years before a drug could be available, and that the next phase of testing will involve using human patients. Hair loss or alopecia is a common complaint in Spain, which has the highest percentage of bald men in the world at 44.5 per cent, according to a survey by Medihair, an online platform for hair loss treatments. Dr López Bran said he had 'noticed a huge increase in inquiries seeking a solution, a truly significant growth in demand, especially among young people who, at the first signs of baldness, want to slow its progression, or even reverse those initial symptoms'. By the age of 50, roughly 50 per cent of men will experience some form of male pattern baldness. Around 25 per cent of will spot signs of thinning or receding as early as 21. Hair transplant surgery has become increasingly popular over the last two decades, with the number of procedures performed globally rising by 76 per cent since 2006. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.